P0408 Prevalence of Celiac Disease in Saudi Children With Type 1 Diabetes Mellitus

Celiac disease in type 1 diabetes mellitus in the Kingdom of Saudi Arabia

“…‡ F/M =60/29=2/1. § Two studies [8,10] in Riyadh region, four studies [9,11,12,13] in the western region and two studies [8,10] 12.0 *Meta analysis is in Table 5 and Table 7. studies).…”

“…40 (7) www.smj.org.sa region (Aseer) (March 2013 and June 2014) and retrospective record based until 2018 in the Southern region (Al-Baha) ( Table 1). [10][11][12][13][14][15][16][17] The pattern of serology and biopsy. Anti-tissue transglutaminase (anti-tTG) was used in 7/8 studies; alone in 4; with anti-endomysium antibody (EMA) in 2; and with anti-gliadin antibody AGA in one.…”

“…27,29 Figure 2 -Sample size and prevalence (seropositivity rate and biopsyproven rate) of celiac disease among type 1 diabetes mellitus patients in the retrieved studies. Al-Ashwal AA et al 2003 10 (1), Saadah OI et al 2004 11 (2), Al-Hussaini A et al 2012 12 (3), Saadah OI et al 2012 13 (4), Al-Agha AE et al 2015 14 (5), Al-Hakami AM 2016 16 (6), Alshareef MA et al 2016 15 (only seropositivity rate) (7), Alghamdi RA et al 2018 17 (only seropositivity rate) (8). 10 1.2 (1996) 20…”

“…The included 8 studies were published between 2003-2018, covering different periods: in Riyadh region (1995-1996 and 2008-2010); in the Western region (retrospectively until 2004, retrospectively until 2015, January 2013-2014 and January 2008 and June 2009); and in the Southern Meta-analysis. Using the CMA program, we performed a meta-analysis for the eight studies concerning seroprevalence of CD in T1DM individuals (articles 10-17), and for 6 studies concerning the prevalence of biopsy-proven CD in T1DM individuals [articles [10][11][12][13][14][15]. Results of the meta-analysis for seropositivity prevalence (Tables 4 and 5; and Figures 3 and 4) show that the prevalence (by fixed model) for the serologically proven CD (by at least one serological test) was 15.8% (95%CI = 14.0-17.7) with high heterogeneity (I 2 =85.84); and the meta-analysis (Tables 6 and 7; and Figures 5 and 6) for the prevalence of the biopsy-proven CD (6 studies; by fixed model) was 12.0% (95%CI = 10.2-14.0) with high heterogeneity (I 2 = 82.71).…”

“…7 In the Kingdom of Saudi Arabia, 8,9 the first study 10 concerning the CD in T1DM appeared in 2003, followed by another 7 studies, the last of which was published in 2018. [10][11][12][13][14][15][16][17] The current study represents characterization and meta-analysis for these studies concerned with CD among patients with T1DM in Kingdom of Saudi Arabia.…”